Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report sent to investors on Saturday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 0.6 %

Brooklyn ImmunoTherapeutics stock opened at $6.54 on Friday. Brooklyn ImmunoTherapeutics has a 12 month low of $6.35 and a 12 month high of $8.31. The business’s 50 day simple moving average is $3.25 and its 200 day simple moving average is $1.69. The company has a market cap of $384.72 million, a price-to-earnings ratio of -2.88 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Dividend Announcement

The company also recently disclosed a monthly dividend, which will be paid on Monday, March 31st. Investors of record on Friday, March 14th will be paid a $0.0862 dividend. The ex-dividend date is Friday, March 14th. This represents a $1.03 annualized dividend and a yield of 15.81%. Brooklyn ImmunoTherapeutics’s payout ratio is -38.33%.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.